Eli Lilly and Company has announced plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States—bringing its total U.S. capital expansion commitments to more than $50 billion since 2020. Three of the future U.S. sites will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly’s supply ch...